Results 101 to 110 of about 168,585 (146)
Paclitaxel-Coated Balloon for Coronary In-Stent Restenosis and De Novo Disease in Chinese Patients. [PDF]
JACC AsiaLu TM +10 more
europepmc +1 more source
Optimal drug regimens for squamous non-small cell lung cancer: a systematic review and a Bayesian network meta-analysis of randomized trials. [PDF]
J Thorac DisYe Y, Li Y, Yan N, Sun L.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1994
Paclitaxel is a novel antineoplastic that effects cytotoxicity by promoting intracellular tubulin polymerization and stabilizes abnormal microtubule structures against depolymerization. Although its clinical development had been hampered by misconceptions about its pharmacology, its scarcity, difficulties extracting it from its natural source ...
D R, Kohler, B R, Goldspiel
openaire +2 more sources
Paclitaxel is a novel antineoplastic that effects cytotoxicity by promoting intracellular tubulin polymerization and stabilizes abnormal microtubule structures against depolymerization. Although its clinical development had been hampered by misconceptions about its pharmacology, its scarcity, difficulties extracting it from its natural source ...
D R, Kohler, B R, Goldspiel
openaire +2 more sources
2019
Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and
Fulwah Yahya, Alqahtani +4 more
openaire +2 more sources
Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and
Fulwah Yahya, Alqahtani +4 more
openaire +2 more sources
The clinical development of paclitaxel and the paclitaxel/carboplatin combination
European Journal of Cancer, 1998Paclitaxel and carboplatin have nonoverlapping toxicities with a broad range of clinical activity. The combination of escalating dose paclitaxel and carboplatin dosed to a fixed area under the curve (AUC) was explored in a series of phase I studies.
G N, Schwartz +6 more
openaire +2 more sources